The Top Line

Inside the commercial growing pains of hemophilia gene therapies

A rare kind of leadership, 30 years in the making

Former FDA Chief Scott Gottlieb talks drug pricing, access and innovation (Sponsored)

Big Pharma bounces back in Q2

The battle of the obesity drug heavyweights

Is Trump’s MFN pricing order more bark than bite?

In this episode of The Top Line, Ayla Ellison introduces Fierce Pharma's Eric Sagonowski and Fraiser Kansteiner, who delve into President Trump's letters to 17 major pharma companies demanding the implementation of Most Favored Nation (MFN) drug pricing in the U.S. The discussion covers the potential impact of MFN pric...

Rebuilding trust: compassionate communication and public health (Sponsored)

Untangling Sarepta’s gene therapy fallout and a growing trust deficit

Making sense of China’s R&D ascent

AI, mentorship and finding your voice in pharma marketing

Biopharma layoffs aren't letting up

Peter Pitts talks FDA direction, industry communication (Sponsored)

Teva’s CEO shares ‘Pivot to Growth’ progress

AbbVie, ADCs and the future of cancer care

Inside Fierce Medtech's Fierce 15

Inside ASCO 2025: Big data drops and a towering campaign

Forging the future of cell therapy: Bayer and BlueRock’s unique journey (Sponsored)

Biopharma briefing: Q1 trends, gene therapy updates and ASCO preview

A Fierce breakdown of the 'most favored nation' executive order

Angela Hwang on her pivot from Big Pharma to biotech